•
Hangzhou-based R-Nanoablation, a minimally invasive medical device developer, has raised over RMB 100 million (USD 13.7 million) in a Series B+ round led by Zhangjiang Haoheng Innovative Equity Investment and Jwell. The funds will accelerate clinical trials and commercialization of its nanosecond pulse electric field (nsPEF) technology platform. Funding DetailsProceeds…